Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

I’m 63 and have been diagnosed with atrial fibrillation. I wonder what you know about medical care and self-care for the ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...